Replimune Group Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Replimune Group Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Replimune Group Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Replimune Group Inc. is REPL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Replimune Group Inc. has its primary listing on NASDAQ. You can trade Replimune Group Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Replimune Group Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Replimune Group Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Replimune Group Inc..